Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Cerebrovascular Accident
Interventions
Abciximab (ReoPro) and Reteplase (Retavase)
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland • Takoma Park, Maryland
Conditions
Cerebrovascular Accident
Interventions
Reopro, Retrovase
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Conditions
Sickle Cell Disease, Hb-SS Disease With Vasoocclusive Pain, Hemoglobin SS Disease With Vasoocclusive Crisis, Other Sickle Cell Disease With Vaso-Occlusive Pain, Hemoglobin SS Disease With Crisis
Interventions
Abciximab, Placebo, Intravenous hydration, Ibuprofen, Parenteral narcotic, Incentive spirometry, Supplemental oxygen
Drug · Other
Lead sponsor
St. Louis University
Other
Eligibility
5 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Myocardial Infarction
Interventions
abciximab placebo; reteplase placebo, abciximab, abciximab, Abciximab; reteplase; abciximab placebo; abciximab, abciximab; reteplase placebo; abciximab placebo; abciximab
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
21 Years and older
Enrollment
2,461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
52
States / cities
Phoenix, Arizona • Covina, California • Modesto, California + 49 more
Completed No phase listed Observational Accepts healthy volunteers

Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients

NCT00379418
Conditions
Coronary Artery Disease
Interventions
Abciximab
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
2
States / cities
Atlanta, Georgia
Completed Not applicable Interventional Results available

The INFUSE - Anterior Myocardial Infarction (AMI) Study

NCT00976521
Conditions
Acute Anterior Myocardial Infarction
Interventions
Abciximab local infusion, No local infusion, Thrombus aspiration
Drug · Other · Procedure
Lead sponsor
Atrium Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
7
States / cities
Takoma Park, Maryland • Charlotte, North Carolina • Greensboro, North Carolina + 4 more
Conditions
Renal Artery Stenosis
Interventions
Renal Artery Stent with Protective Device/Drug
Device
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Toledo, Ohio
Completed No phase listed Observational Results available

ClearWay Rx Readmission Registry

NCT01673893
Conditions
Acute Myocardial Infarction
Interventions
ClearWay™ Rx catheter
Device
Lead sponsor
Cardiovascular Institute of the South Clinical Research Corporation
Other
Eligibility
18 Years to 80 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Lafayette, Louisiana
Conditions
Stable Angina
Interventions
Intravenous Glycoprotein inhibitor + ASA, Clopidogrel, Antiplatelet Therapy (ASA, Clopidogrel)
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York